The results from Lung MAP are used to identify effective new treatments for NSCLC and to enhance our understanding of the genetic underpinnings of the disease. Successful treatments may be fast-tracked for FDA approval, allowing them to reach patients more quickly. Additionally, the data collected from the trial can inform future research and help in the development of new therapeutic strategies.
